Literature DB >> 12685622

The relative utility of cardiac troponin I, creatine kinase-MBmass, and myosin light chain-1 in the long-term risk stratification of patients with chest pain.

Graham S Hillis1, Pamela Taggart, Delana Wardlaw, Lorraine Hillis, Ning Zhao, William C Dalsey, Antoinette Mangione.   

Abstract

BACKGROUND: Sensitive and specific cardiac markers convey important short-term prognostic information about patients with an acute coronary syndrome. There are, however, few data assessing their value as long-term predictors. HYPOTHESIS: The aim of the current study was to assess the relative value of three such markers and clinical characteristics in determining the long-term prognosis of patients with chest pain.
METHODS: Cardiac troponin I (cTnI), myosin light chain-(MLC-1), and creatine kinase-MBmass levels were obtained on admission (0 h) and at 4, 8, 16, and 24 h in 208 patients with chest pain. Eligible subjects were determined, at the time of hospital admission, to be at >7% risk of acute myocardial infarction (MI), but without new ST-segment elevation on their presenting electrocardiogram. Follow-up was performed a median of 28 (range 1-46) months later. The primary study endpoint was death or nonfatal MI, subsequent to the index admission.
RESULTS: Cardiac TnI levels > or = 0.2 ng/ml (odds ratio [OR] 1.93, 95% confidence interval [CI] 1.09-3.40) and MLC-1 levels > or = 1 ng/ml (OR 3.24, 95% CI 1.83-5.73) were both significant predictors of death or MI during long-term follow-up; MLC-1 was, however, the only independent biochemical predictor (OR 2.11,95% CI 1.14-3.93).
CONCLUSIONS: Both cTnl and MLC-1 predict the long-term outcome of patients with chest pain, but, in this cohort, MLC-1 proved to be a better predictor of mortality and nonfatal acute MI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12685622      PMCID: PMC6654590          DOI: 10.1002/clc.4960260310

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  28 in total

Review 1.  Acute coronary syndromes: diagnosis.

Authors:  P Klootwijk; C Hamm
Journal:  Lancet       Date:  1999-06       Impact factor: 79.321

2.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Authors:  B Lindahl; H Toss; A Siegbahn; P Venge; L Wallentin
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

3.  Racial and ethnic differences in the use of cardiovascular procedures: findings from the California Cooperative Cardiovascular Project.

Authors:  E Ford; J Newman; K Deosaransingh
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

4.  Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: the potential role of early percutaneous revascularization.

Authors:  S Fuchs; R Kornowski; R Mehran; L F Satler; A D Pichard; K M Kent; M K Hong; S Slack; G W Stone; M B Leon
Journal:  J Am Coll Cardiol       Date:  1999-11-15       Impact factor: 24.094

5.  Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.

Authors:  C Heeschen; C W Hamm; B Goldmann; A Deu; L Langenbrink; H D White
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

6.  Prospective study correlating fibrinopeptide A, troponin I, myoglobin, and myosin light chain levels with early and late ischemic events in consecutive patients presenting to the emergency department with chest pain.

Authors:  A Sonel; B M Sasseen; N Fineberg; N Bang; R L Wilensky
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

7.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.

Authors:  L Wallentin; B Lagerqvist; S Husted; F Kontny; E Ståhle; E Swahn
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

8.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

Authors:  C W Hamm; C Heeschen; B Goldmann; A Vahanian; J Adgey; C M Miguel; W Rutsch; J Berger; J Kootstra; M L Simoons
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

9.  Utility of cardiac troponin I, creatine kinase-MB(mass), myosin light chain 1, and myoglobin in the early in-hospital triage of "high risk" patients with chest pain.

Authors:  G S Hillis; N Zhao; P Taggart; W C Dalsey; A Mangione
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

10.  The prognostic value of serum troponin T in unstable angina.

Authors:  C W Hamm; J Ravkilde; W Gerhardt; P Jørgensen; E Peheim; L Ljungdahl; B Goldmann; H A Katus
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.